# A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients

> **NCT01199939** · PHASE2 · COMPLETED · sponsor: **Tibotec, Inc** · enrollment: 54 (actual)

## Conditions studied

- Human Immunodeficiency Virus (HIV)

## Interventions

- **DRUG:** Etravirine
- **DRUG:** Ritonavir
- **DRUG:** Darunavir

## Key facts

- **NCT ID:** NCT01199939
- **Lead sponsor:** Tibotec, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2013-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01199939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01199939, "A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients". Retrieved via AI Analytics 2026-09-17 from https://api.ai-analytics.org/clinical/NCT01199939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*